PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for fo	orm 1449/PT	0	Со	mplete if known
			Application Number	10/034,950
INFORMA'	TION DISC	CLOSURE	Filing Date	December 26, 2001; Conf. No. 9344
STATEMENT BY APPLICANT			First Named Inventor	Bhami Shenoy et al.
			Art Unit	1656
(use as mar	ny sheets as	necessary)	Examiner Name	Suzanne Marie Noakes
Sheet 1	of	1	Attorney Docket Number	VPI/00-08 RCE US

DEC 17 2007

		FOR	EIGN PATEN	T DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	_	Pages, Columns, Lines, Where Relevant	
initials*		Country Code <sup>1</sup> – Number <sup>2</sup> - Kind Code <sup>3</sup>	MM-DD-YYYY	Country	Passages or Relevant Figures Appear	٣
		WO 00/77281	12/21/2000	PCT		

<del></del>		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published			
		Chayen et al., Recent Advances in Methodology for Crystallization of Biological Macromolecules," <i>Journal of Crystal Growth</i> , 198-199:649-655 (1999).			
		Hainsworth et al., "Monoclonal antibody therapy in lymphoid malignancies," 5(5):376-384 (2000).			
		McPherson et al., "Crystallization of Macromolecules: General Principles," Methods in Enzymology 114:112-120 (1985).			
		Saphire et al., "Crystallization and Preliminary Structure Determination of an Intact Human Immunoglobulin, b12: An Antibody that Broadly Neutralizes Primary Isolates of HIV-1," Acta Cryst., D57:168-171 (2001).			
		Schwarz et al., "Anti-TNF-Alpha Therapy as Clinical Intervention for Periprosthetic Osteolysis," <i>Arthritis Research</i> , 2:165-168 (2000).			
		Van Assche et al., "Anti-TNF agents in Crohn's Disease," Expert Opinion in Investigational Drugs, 9(1):103-111 (2000)			

Examiner	/Alexander Kim/	Date	02/06/2008
Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents P.O. Box 1450, Alexandria Commerce, P



## PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if known		
				Application Number	10/034,950	
INFO	DRMATION	DISC	CLOSURE	Filing Date	December 26, 2001; Conf. No. 9344	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Bhami Shenoy et al.	
				Art Unit	1656	
(use as many sheets as necessary)		Examiner Name	Suzanne Marie Noakes			
Sheet	1	of	1	Attorney Docket Number	VPI/00-08 RCE US	

Examiner	Cite	Foreign Patent Document	Publication Date		Pages, Columns, Lines, Where Relevant	
initials* No.1	Country Code <sup>1</sup> - Number <sup>2</sup> - Kind Code <sup>3</sup>	MM-DD-YYYY	Country	Passages or Relevant Figures Appear	1.	
		WO 00/77281	12/21/2000	PCT		

-	NON PATENT LITERATURE DOCUMENTS		
Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	7*	Duplicate copy of
	Chayen et al., Recent Advances in Methodology for Crystallization of		1st page
000000000000000000000000000000000000000	(1999).	***************************************	<del>3000000000000000000000000000000000000</del>
	Hainsworth et al., "Monoclonal antibody therapy in lymphoid malignancies,"		
000000000000000000000000000000000000000	<del>*************************************</del>	***************************************	***************************************
200000000000000	McPherson et al., "Crystallization of Macromolecules: General Principles,"  Methods in Framelogy 114:112-120 (1985)		000000000000000000000000000000000000000
	Saphire et al., "Crystallization and Preliminary Structure Determination of an Intact Human Immunoglobulin, b12: An Antibody that Broadly Neutralizes Primary Isolates of HIV-1," Acta Cryst., D57:168-171 (2001).		
BOOKER	Schwarz et al., "Anti-TNF-Alpha Therapy as Clinical Intervention for Periprosthetic Osteolysis," Arthritis Research, 2:165-168 (2000).	Secondesis	
000000000000000000000000000000000000000	Van Assche et al., "Anti-TNF agents in Crohn's Disease," Expert Opinion in Investigational Drugs, 9(1):103-111 (2000)	0,0000	
		Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published  Chayen et al., Recent Advances in Methodology for Crystallization of Biological Macromolecules." Journal of Crystal Growth, 198-199:649-655 (1999).  Hainsworth et al., "Monoclonal antibody therapy in lymphoid malignancies," 3(3):376-384 (2000).  McPherson et al., "Crystallization of Macromolecules: General Principles," Methods in Engineering 114:112-120 (1985).  Saphire et al., "Crystallization and Preliminary Structure Determination of an Intact Human Immunoglobulin, b12: An Antibody that Broadly Neutralizes Primary Isolates of HIV-1," Acta Cryst., D57:168-171 (2001).  Schwarz et al., "Anti-TNF-Alpha Therapy as Clinical Intervention for Periprosthetic Osteolysis," Arthritis Research, 2:165-168 (2000).  Van Assche et al., "Anti-TNF agents in Crohn's Disease," Expert Opinion in	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published    Chayen et al., Recent Advances in Methodology for Crystallization of Biological Macromolecules," Journal of Crystal Growth, 198-199:649-655 (1999).    Hainsworth et al., "Monoclonal antibody therapy in lymphoid malignancies," 3(3):376-384 (2000).    McPherson et al., "Crystallization of Macromolecules: General Principles," Mathods in Enginelogy 114:112-120 (1985)    Saphire et al., "Crystallization and Preliminary Structure Determination of an Intact Human Immunoglobulin, b12: An Antibody that Broadly Neutralizes Primary Isolates of HIV-1," Acta Cryst., D57:168-171 (2001).    Schwarz et al., "Anti-TNF-Alpha Therapy as Clinical Intervention for Periprosthetic Osteolysis," Arthritis Research, 2:165-168 (2000).    Van Assche et al., "Anti-TNF agents in Crohn's Disease," Expert Opinion in

Examiner	/Alexander Kim/	Date 02/06/2008	
Signature	77 1107011001 71111	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria VA223 HA50-DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS SEND TO THIS OF THIS OF THE SUIT HE SEND TO THE SUIT HE SUIT